Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company developing precision therapies for solid tumors, has announced its participation in two upcoming investor conferences. The company will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, where senior management will engage in one-on-one investor meetings. Additionally, Aura will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, featuring both investor meetings and a virtual presentation by CEO Elisabet de los Pinos, PhD.
The virtual presentation at the H.C. Wainwright conference will be available at 7:00 am ET on September 9, 2024, accessible via the company's website and the conference platform. This presentation will remain archived on Aura's website for 90 days following the event, providing extended access for interested parties.
Aura Biosciences (NASDAQ: AURA), una società biotech in fase clinica che sviluppa terapie mirate per i tumori solidi, ha annunciato la sua partecipazione a due prossimi eventi per investitori. L'azienda parteciperà al 22° Annual Global Healthcare Conference di Morgan Stanley il 4 settembre 2024, dove la direzione senior sarà coinvolta in incontri individuali con gli investitori. Inoltre, Aura prenderà parte al 26° Annual Global Investment Conference di H.C. Wainwright il 9 settembre 2024, che prevede incontri con gli investitori e una presentazione virtuale del CEO Elisabet de los Pinos, PhD.
La presentazione virtuale durante la conferenza H.C. Wainwright sarà disponibile alle 7:00 ET del 9 settembre 2024, accessibile tramite il sito web dell'azienda e la piattaforma della conferenza. Questa presentazione rimarrà archiviata sul sito di Aura per 90 giorni dopo l'evento, offrendo accesso prolungato per le parti interessate.
Aura Biosciences (NASDAQ: AURA), una empresa biotecnológica en etapa clínica que desarrolla terapias precisas para tumores sólidos, ha anunciado su participación en dos próximas conferencias de inversores. La empresa asistirá a la 22ª Conferencia Anual Global de Atención Médica de Morgan Stanley el 4 de septiembre de 2024, donde la alta dirección se reunirá uno a uno con inversores. Además, Aura participará en la 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright el 9 de septiembre de 2024, que incluirá reuniones con inversores y una presentación virtual de la CEO Elisabet de los Pinos, PhD.
La presentación virtual en la conferencia de H.C. Wainwright estará disponible a las 7:00 am ET del 9 de septiembre de 2024, accesible a través del sitio web de la empresa y la plataforma de la conferencia. Esta presentación permanecerá archivada en el sitio web de Aura durante 90 días después del evento, proporcionando acceso extendido a las partes interesadas.
아우라 바이오사이언스 (NASDAQ: AURA)는 고형 종양을 위한 정밀 치료제를 개발하는 임상 단계의 생명공학 회사로, 두 개의 예정된 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 2024년 9월 4일에 열리는 모건 스탠리 제22회 연례 글로벌 헬스케어 회의에 참석할 예정이며, 이 회의에서는 고위 경영진이 개별 투자자와 대면 회의를 진행합니다. 또한 아우라는 2024년 9월 9일에 열리는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참여할 예정이며, 여기에서는 투자자 회의와 CEO 엘리사베트 데 로스 피노스 박사의 가상 발표가 포함됩니다.
H.C. 웨인라이트 회의에서의 가상 발표는 2024년 9월 9일 오전 7시(동부표준시)부터 회사 웹사이트와 회의 플랫폼을 통해 이용 가능하며, 이 발표는 행사 후 90일 동안 아우라의 웹사이트에 아카이브되어 관심 있는 모든 이들이 이용할 수 있도록 합니다.
Aura Biosciences (NASDAQ: AURA), une entreprise de biotechnologie en phase clinique développant des thérapies de précision pour les tumeurs solides, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise assistera à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 4 septembre 2024, où la direction senior participera à des réunions individuelles avec des investisseurs. De plus, Aura participera à la 26ème Conférence Annuelle Mondiale sur l'Investissement de H.C. Wainwright le 9 septembre 2024, qui comprendra des réunions avec les investisseurs et une présentation virtuelle par la PDG Elisabet de los Pinos, PhD.
La présentation virtuelle lors de la conférence H.C. Wainwright sera disponible à 7h00 ET le 9 septembre 2024, accessible via le site web de l'entreprise et la plateforme de la conférence. Cette présentation restera archivée sur le site d'Aura pendant 90 jours après l'événement, offrant ainsi un accès prolongé aux parties intéressées.
Aura Biosciences (NASDAQ: AURA), ein biotechnologisches Unternehmen in klinischer Phase, das Präzisionsbehandlungen für solide Tumoren entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird am 22. jährlichen Global Healthcare Conference von Morgan Stanley am 4. September 2024 teilnehmen, wo das Senior Management Einzeltreffen mit Investoren abhalten wird. Darüber hinaus wird Aura an der 26. jährlichen Global Investment Conference von H.C. Wainwright am 9. September 2024 teilnehmen, die sowohl Investorenmeetings als auch eine virtuelle Präsentation des CEO Elisabet de los Pinos, PhD, umfasst.
Die virtuelle Präsentation auf der H.C. Wainwright-Konferenz wird am 9. September 2024 um 7:00 Uhr ET verfügbar sein und ist über die Unternehmenswebsite sowie die Konferenzplattform zugänglich. Diese Präsentation bleibt für 90 Tage nach der Veranstaltung auf der Website von Aura archiviert, sodass interessierte Parteien langfristig Zugang haben.
- None.
- None.
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. Members of Aura’s senior management team will participate in one-on-one investor meetings.
- H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024.
Members of Aura’s senior management team will participate in one-on-one investor meetings. A virtual presentation by Elisabet de los Pinos, PhD, Chief Executive Officer, will be available on Monday, September 9, 2024 at 7:00 am ET at https://journey.ct.events.
The presentation at the H.C. Wainwright conference will also be available at such time on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where it will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. We are evaluating the safety and efficacy of bel-sar as a potential vision-sparing therapy in an ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early-stage choroidal melanoma. Bel-sar is also being evaluated in additional solid cancers, including bladder cancer. Our mission is to develop vision and organ-sparing therapies to improve patient outcomes in cancer. Aura is headquartered in Boston, MA. For more information, visit aurabiosciences.com. Visit us @AuraBiosciences and on LinkedIn.
Investor and Media Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
FAQ
What investor conferences is Aura Biosciences (AURA) attending in September 2024?
Will Aura Biosciences (AURA) be presenting at the H.C. Wainwright conference?
How can investors access Aura Biosciences' (AURA) presentation from the H.C. Wainwright conference?
How long will Aura Biosciences' (AURA) presentation from the H.C. Wainwright conference be available online?
